Galectin Therapeutics (GALT) Net Cash Flow (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Net Cash Flow of -$3.6 million for Q1 2026, up 53.06% year-over-year from -$2.4 million in Q1 2025, and down 158.81% quarter-over-quarter from $6.1 million in Q4 2025.
Galectin Therapeutics (GALT) Net Cash Flow (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$3.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 53.06% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at $6.7 million (up 141.26% YoY), while the FY2025 annual figure was $2.6 million, up 124.43% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$3.6 million, down from $6.1 million in the prior quarter.
- The five-year high for Net Cash Flow was $6.3 million in Q2 2025, with the low at -$11.9 million in Q4 2024.
- The 5-year median for Net Cash Flow is -$793000.0 (2023), against an average of -$1.5 million.
- Peak annual rise in Net Cash Flow reached 1143.11% in 2024, while the deepest fall reached 326.87% in 2024.
- Galectin Therapeutics' Net Cash Flow stood at $2.8 million in 2022, then surged by 90.62% to $5.3 million in 2023, then slumped by 326.87% to -$11.9 million in 2024, then surged by 151.4% to $6.1 million in 2025, then slumped by 158.81% to -$3.6 million in 2026.
- Business Quant data shows GALT's Net Cash Flow at -$3.6 million in Q1 2026, $6.1 million in Q4 2025, and -$2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | -3.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.61 Mn |
| Mar 31, 2026 | -3.61 Mn |
| Dec 31, 2025 | 6.14 Mn |
| Dec 31, 2025 | 6.14 Mn |
| Sep 30, 2025 | -2.20 Mn |
| Sep 30, 2025 | -2.20 Mn |
| Jun 30, 2025 | 6.33 Mn |
| Jun 30, 2025 | 6.33 Mn |
| Mar 31, 2025 | -7.69 Mn |
| Mar 31, 2025 | -7.69 Mn |
| Dec 31, 2024 | -11.94 Mn |
| Dec 31, 2024 | -11.94 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 2.08 Mn |
| Mar 31, 2024 | -2.10 Mn |
| Mar 31, 2024 | -2.10 Mn |
| Dec 31, 2023 | 5.26 Mn |
| Dec 31, 2023 | 5.26 Mn |